R Rimmy Malhotra Is Appointed to the BOD of InfuSystem: Effective September 20, 2022

R Rimmy Malhotra will serve as a director until he stands for election at InfuSystem’s next Annual Shareholders meeting in May 2023.

Scott Shuda, Chairman of InfuSystem’s Board of Directors, said, “We are pleased to welcome Rimmy as a new independent director on InfuSystem’s Board. Rimmy first invested in the Company in 2012, and has an earned reputation as a particularly attentive shareholder. With his joining the Board, the Company will gain increased benefit from his perspective and insights, particularly regarding investments and capital allocation as we continue to execute on our long-term growth strategy.”

“I have long admired InfuSystem, and believe the Company has opportunity to significantly expand its business to the benefit of all stakeholders,” said Mr. Malhotra. He continued, “Managing through growth transitions is always a challenge, and this can be particularly trying for small public companies. I look forward to being part of the governance process at InfuSystem and doing my part to help the Company achieve its goals.”

Mr. Malhotra is the Founder of The Nicoya Fund LP, a private investment partnership. Mr. Malhotra currently serves as a Director and Vice Chairman of HireQuest Inc., an asset light staffing franchisor, since 2016. Since November 2019, Mr. Malhotra has been a member of the Board of Directors of Optex Systems Holdings, Inc., an optical systems manufacturer, and also sits on the board of Scotts Liquid Gold. Mr. Malhotra holds an MBA in Finance from The Wharton School and a Master’s degree in International Relations from the University of Pennsylvania where he is a Lauder Fellow. M

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.